8-K: Estrella's EB103 Advances to Phase II with 100% CR Rate

Estrella Immunopharma's EB103 CD19 CAR-T therapy has advanced to Phase II of its STARLIGHT-1 trial following positive safety and efficacy data, including a 100% complete response rate in the high-dose Phase I cohort.

Summary

• Estrella Immunopharma, Inc. announced the advancement of its STARLIGHT-1 trial for EB103 into Phase II.
• An independent Data Safety Monitoring Board (DSMB) confirmed EB103's favorable safety profile, reporting no treatment-related serious adverse events (SAEs) in the Phase I dose escalation phase (n=9).
• The DSMB recommended advancing the trial to Phase II at the Recommended Phase II Dose (RP2D).
• The high-dose cohort of Phase I achieved a 100% complete response (CR) rate at Month 1 in all evaluable patients.
• The trial included high-risk patients, such as one with Central Nervous System (CNS) lymphoma, who are often ineligible for currently available commercial CD19 products.
• EB103 is a CD19-redirected ARTEMIS T-cell therapy, utilizing technology licensed from Eureka Therapeutics, Inc.
• The expansion phase (Phase II) will be a multi-center, open-label study to further evaluate safety and efficacy in patients (18 years of age) with relapsed/refractory (R/R) B-cell non-Hodgkin's lymphoma (NHL).
• Data from the expansion cohort will inform the pivotal trial strategy for EB103.
• Current active sites for the trial include UC Davis Comprehensive Cancer Center and Baylor Scott & White Research Institute.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to the successful completion of Phase I with excellent safety and a 100% complete response rate in the high-dose cohort, leading to a positive DSMB recommendation and advancement to Phase II. This represents a significant de-risking event for a clinical-stage biopharmaceutical company.

Positives

• EB103 demonstrated a favorable safety profile with no treatment-related serious adverse events (SAEs) reported in the Phase I dose escalation phase (n=9).
• The high-dose cohort in Phase I achieved a 100% complete response (CR) rate at Month 1 in all evaluable patients.
• The independent Data Safety Monitoring Board (DSMB) recommended advancing the STARLIGHT-1 trial to Phase II at the Recommended Phase II Dose (RP2D), indicating strong confidence in the drug's profile.
• EB103 showed potential to treat high-risk patients, including those with CNS lymphoma, who are often ineligible for existing commercial CD19 CAR-T therapies.
• The company believes EB103 has the potential to be a best-in-class CD19 CAR-T therapy and significantly expand the commercial reach of cell therapy.

Risks

• Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Risk Factors and elsewhere in the company's filings with the Securities and Exchange Commission.

Future Outlook

Estrella Immunopharma anticipates that EB103's advancement into Phase II will further evaluate its safety and preliminary efficacy, with data from this expansion cohort intended to inform the pivotal trial strategy. The company believes EB103 has the potential to overcome toxicity barriers of current CD19 CAR-T therapies, expand the commercial reach of cell therapy, and deliver a best-in-class solution to a broader NHL population, including high-risk subgroups.

Management Comments

• "The advancement of EB103 into the expansion phase of STARLIGHT-1 is a pivotal milestone for Estrella," said Cheng Liu, PhD, Chief Executive Officer of Estrella.
• "The excellent safety profile and a 100% complete response rate observed in the high-dose cohort in Phase I demonstrated EB103’s potential to overcome the toxicity barriers that have historically restricted CD19 CAR-T use."
• "We believe EB103 may significantly expand the commercial reach of cell therapy and deliver a best-in-class solution to a broader NHL population, including high-risk subgroups previously ineligible for commercial CAR-T."

Industry Context

This announcement positions Estrella Immunopharma as a significant player in the competitive CAR-T cell therapy landscape, particularly for B-cell malignancies. The focus on overcoming toxicity barriers and treating high-risk patients, including those with CNS lymphoma, addresses a critical unmet need in the relapsed/refractory B-cell non-Hodgkin's lymphoma population, potentially expanding the addressable market beyond current commercial CD19 CAR-T offerings.

Comparison to Industry Standards

• EB103's favorable safety profile with no treatment-related SAEs and its ability to treat high-risk patients, including those with CNS lymphoma, suggests a potential advantage over currently available commercial CD19 products.
• The filing implies a comparison to existing commercial CD19 CAR-T therapies such as Novartis' Kymriah, Gilead/Kite's Yescarta, and Bristol Myers Squibb's Breyanzi, by stating EB103's potential to serve patients 'ineligible for currently available commercial CD19 products' and to 'overcome the toxicity barriers' that have historically restricted their use.
• The claim of a 'best-in-class CD19 CAR-T therapy' positions EB103 against the efficacy and safety profiles of these established therapies, aiming for superior outcomes or broader applicability.

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical progress, de-risking the lead product candidate and potentially increasing company valuation.
• Patients: Potential for a new, safer, and more effective treatment option for relapsed/refractory B-cell non-Hodgkin's lymphoma, especially for high-risk patients currently ineligible for other therapies.
• Employees: Positive impact through continued progress in drug development and potential for future commercial success.
• Regulatory Authorities: Will closely monitor the Phase II trial results given the promising early data and the potential for a novel CAR-T therapy.

Next Steps

• Continue the multi-center, open-label Phase II expansion phase to further evaluate the safety and efficacy of EB103 at the Recommended Phase II Dose (RP2D).
• Utilize data from the expansion cohort to determine the pivotal trial strategy for EB103.

Key Dates

Recommendation

The strong Phase I results, including a 100% complete response rate in the high-dose cohort and a favorable safety profile with no SAEs, are exceptionally positive for a clinical-stage oncology asset. The independent DSMB's recommendation to advance to Phase II at the RP2D further validates the drug's potential. This data suggests EB103 could be a 'best-in-class' therapy, addressing an unmet need in high-risk patient populations. For a company at this stage, such robust clinical data significantly de-risks the development pathway and indicates substantial future value creation potential, warranting a strong buy recommendation for investors with an appropriate risk tolerance for biotech.

Keywords

Estrella Immunopharma, EB103, STARLIGHT-1, Phase II, CAR-T therapy, CD19, Non-Hodgkin's Lymphoma, NHL, Relapsed/Refractory, ARTEMIS T-cell, Clinical Trial, Biopharmaceutical, Oncology